Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Gastroparesis Drugs Market

Gastroparesis Drugs Market Size

Report ID: GMI9322
Published Date: May 2024
Report Format: PDF

Download Free Sample

Gastroparesis Drugs Market Size

Gastroparesis Drugs Market size was valued at USD 5.9 billion in 2023 and is growing at a CAGR of 5% between 2024 and 2032, driven by factors such increased prevalence of diabetes worldwide due to rapid urbanization, lifestyles, and rising rates of regular alcohol and tobacco consumption.

To get key market trends

Download Free Sample

For instance, as per the article published by Multidisciplinary Digital Publishing Institute (MDPI) in February 2024, it was found that approximately 9.3% of individuals with diabetes may experience the onset of gastroparesis during their illness. This risk appears to be heightened in individuals with long-standing type 1 diabetes or type 2 diabetes lasting ten years or more. Thus, the rapid increase in the prevalence of diabetes globally is expected to increase the incidence of diabetic gastroparesis that propel the demand for gastroparesis drugs, thereby boosting the growth of the market. Furthermore, the introduction of innovative drugs, by the manufacturers, aimed at symptom management, particularly for nausea and vomiting, is an important driving factor.

Gastroparesis Drugs Market Report Attributes
Report Attribute	Details
Base Year:	2023
Gastroparesis Drugs Market Size in 2023:	USD 5.9 Billion
Forecast Period:	2024 - 2032
Forecast Period 2024 - 2032 CAGR:	5%
2032 Value Projection:	USD 9.1 Billion
Historical Data for:	2021 - 2023
No. of Pages:	182
Tables, Charts & Figures:	298
Segments covered:	Drug Class, Disease Type, Route of Administration, Drug Type, Distribution Channel, and Region
Growth Drivers:	Rising incidence of gastroparesis Growing patient preference for non-invasive treatment Rising awareness and diagnosis rate
Pitfalls & Challenges:	Availability of limited treatment options Regulatory challenges

Learn more about the key segments shaping this market

Download Free Sample

Gastroparesis means stomach paralysis - it is a condition affecting the nerves and muscles in the stomach. It interferes with the muscle activity (peristalsis) that moves food through the stomach and into the small intestine. Gastroparesis drugs are medications used to manage the symptoms of gastroparesis; a condition characterized by delayed emptying of the stomach. These medications aim to improve gastric motility and alleviate symptoms such as nausea, vomiting, bloating, and abdominal pain.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Gastroparesis drugs industry size was USD 5.9 billion in 2023 and will depict a 5% CAGR from 2024 to 2032 due to the increasing prevalence of gastroparesis globally, particularly among diabetic patients, rising awareness about the condition, and advancements in diagnostic techniques.

The diabetes gastroparesis segment captured 44.6% of the market share in 2023, driven by the escalating prevalence of diabetes worldwide coupled with the consequential rise in gastroparesis cases among diabetic patients.

North America gastroparesis drugs industry will record USD 3.5 billion by 2032, attributed to advanced healthcare infrastructure, high awareness about gastroparesis, and robust R&D activities.

Key gastroparesis drug firms are Abbott Laboratories, AbbVie Inc., AstraZeneca PLC, Bayer AG, Cipla Ltd., Evoke Pharma, Pfizer Inc., Salix Pharmaceuticals, Takeda Pharmaceutical, Inc., and Teva Pharmaceutical Inc., among others.